Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
1.180
-0.070 (-5.60%)
At close: Dec 5, 2025, 4:00 PM EST
1.240
+0.060 (5.08%)
After-hours: Dec 5, 2025, 6:55 PM EST
Citius Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Jun '25 Jun 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 |
| Selling, General & Admin | 30.71 | 30.09 | 21.91 | 15.66 | 11.29 | 8.9 | |
| Research & Development | 10.43 | 11.91 | 14.82 | 17.66 | 12.24 | 8.81 | |
| Operating Expenses | 41.14 | 42 | 36.73 | 33.32 | 23.53 | 17.71 | |
| Operating Income | -41.14 | -42 | -36.73 | -33.32 | -23.53 | -17.71 | |
| Interest Expense | -0.17 | - | - | - | -0.01 | -0.02 | |
| Interest & Investment Income | 0.17 | 0.76 | 1.18 | 0.25 | 0.26 | 0.07 | |
| Other Non Operating Income (Expenses) | - | - | - | - | - | 0.11 | |
| EBT Excluding Unusual Items | -41.14 | -41.24 | -35.55 | -33.06 | -23.28 | -17.55 | |
| Gain (Loss) on Sale of Assets | - | 2.39 | 3.59 | - | - | - | |
| Other Unusual Items | - | - | - | - | 0.23 | - | |
| Pretax Income | -41.14 | -38.85 | -31.97 | -33.06 | -23.05 | -17.55 | |
| Income Tax Expense | 0.94 | 0.58 | 0.58 | 0.58 | - | - | |
| Earnings From Continuing Operations | -42.07 | -39.43 | -32.54 | -33.64 | -23.05 | -17.55 | |
| Minority Interest in Earnings | 1.81 | 0.29 | - | - | - | - | |
| Net Income | -40.26 | -39.14 | -32.54 | -33.64 | -23.05 | -17.55 | |
| Preferred Dividends & Other Adjustments | 0.73 | 1.05 | 1.15 | - | 1.45 | - | |
| Net Income to Common | -40.99 | -40.19 | -33.69 | -33.64 | -24.51 | -17.55 | |
| Shares Outstanding (Basic) | 9 | 7 | 6 | 6 | 4 | 2 | |
| Shares Outstanding (Diluted) | 9 | 7 | 6 | 6 | 4 | 2 | |
| Shares Change (YoY) | 31.75% | 11.16% | 3.57% | 34.52% | 177.28% | 94.25% | |
| EPS (Basic) | -4.78 | -5.97 | -5.57 | -5.76 | -5.64 | -11.20 | |
| EPS (Diluted) | -4.78 | -5.97 | -5.57 | -5.76 | -5.64 | -11.20 | |
| Free Cash Flow | -20.58 | -28.2 | -29.06 | -28.36 | -24.26 | -16.93 | |
| Free Cash Flow Per Share | -2.40 | -4.19 | -4.80 | -4.85 | -5.58 | -10.81 | |
| EBITDA | -41.14 | -41.99 | -36.73 | -33.31 | -23.53 | -17.71 | |
| D&A For EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | |
| EBIT | -41.14 | -42 | -36.73 | -33.32 | -23.53 | -17.71 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.